HBM Holdings' Obesity Drug Found to Have Favorable Profile in Preclinical Data

MT Newswires Live05-18

HBM Holdings (HKG:2142) said its LET003 drug candidate was found to have a more favorable drug-profile in the body than several competing molecules, according to a Monday filing with the Hong Kong bourse.

According to preclinical data, the drug significantly enhanced fat reduction and preserved lean mass when combined with Novo Nordisk's weight loss drug semaglutide.

Specifically, in an obesity model using wild-type mice, the drug combo decreased fat mass by 76% compared with 34.7% for semaglutide alone.

The AI-enabled drug also promoted lean mass at lower doses, with effects comparable to those seen with higher doses of Novartis' bimagrumab, the firm said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636785048?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-18 10:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636785048","market":"sh","top_or_hot":-1,"title":"HBM Holdings' Obesity Drug Found to Have Favorable Profile in Preclinical Data","media":"MT Newswires Live","content":"<html><body><p> HBM Holdings (HKG:2142) said its LET003 drug candidate was found to have a more favorable drug-profile in the body than several competing molecules, according to a Monday filing with the Hong Kong bourse.</p><p>According to preclinical data, the drug significantly enhanced fat reduction and preserved lean mass when combined with <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s weight loss drug semaglutide.</p><p>Specifically, in an obesity model using wild-type mice, the drug combo decreased fat mass by 76% compared with 34.7% for semaglutide alone.</p><p>The AI-enabled drug also promoted lean mass at lower doses, with effects comparable to those seen with higher doses of Novartis' bimagrumab, the firm said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM Holdings' Obesity Drug Found to Have Favorable Profile in Preclinical Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM Holdings' Obesity Drug Found to Have Favorable Profile in Preclinical Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-18 10:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> HBM Holdings (HKG:2142) said its LET003 drug candidate was found to have a more favorable drug-profile in the body than several competing molecules, according to a Monday filing with the Hong Kong bourse.</p><p>According to preclinical data, the drug significantly enhanced fat reduction and preserved lean mass when combined with <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s weight loss drug semaglutide.</p><p>Specifically, in an obesity model using wild-type mice, the drug combo decreased fat mass by 76% compared with 34.7% for semaglutide alone.</p><p>The AI-enabled drug also promoted lean mass at lower doses, with effects comparable to those seen with higher doses of Novartis' bimagrumab, the firm said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2636785048","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2636785048","pubTimestamp":1779070120,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"HBM Holdings (HKG:2142) said its LET003 drug candidate was found to have a more favorable drug-profile in the body than several competing molecules, according to a Monday filing with the Hong Kong bou","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","DRAM":"Roundhill Memory ETF","BK1583":"高瓴概念","02142":"和铂医药-B","BK1574":"生物医药B类股"},"translate_title":"HBM Holdings的肥胖药物在临床前数据中表现良好","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DRAM":1.5,"02142":1},"content_text":"HBM Holdings (HKG:2142) said its LET003 drug candidate was found to have a more favorable drug-profile in the body than several competing molecules, according to a Monday filing with the Hong Kong bourse.According to preclinical data, the drug significantly enhanced fat reduction and preserved lean mass when combined with Novo Nordisk's weight loss drug semaglutide.Specifically, in an obesity model using wild-type mice, the drug combo decreased fat mass by 76% compared with 34.7% for semaglutide alone.The AI-enabled drug also promoted lean mass at lower doses, with effects comparable to those seen with higher doses of Novartis' bimagrumab, the firm said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636785048","isCrawlerRequest":true}